

Erratum to Correct Errors in Text

Adam Ioannou

National Amyloidosis Centre, University College London, Royal Free Campus, London, UK

This corrects the article: "Ioannou A. Evolution of Disease-modifying Therapy for Transthyretin Cardiac Amyloidosis. *Heart International*. 2024;18(1):30-37"

Two typography errors were included incorrectly due to an editorial error.

In *Table 1*, "eplontersen" was incorrectly written as "eplomtersen". This has been corrected in the text.

In the section "Eplontersen", the administration schedule should be written as every 4 weeks, rather than every 3 weeks, as per the correct information provided in *Table 1*. This has been corrected in the text as follows:

"This superior delivery system has enabled eplontersen to be up to 50-fold more potent than inotersen at reducing TTR expression, which in turn allows it to be administered every 4 weeks, rather than the weekly subcutaneous injection required to administer inotersen.⁵⁸"

Access: This article is freely accessible at touchCARDIO.com © Touch Medical Media 2024.

Published Online: 2 August 2024

Citation: *Heart International*. 2024;18(2):3